Efficacy of Saussurea costus (Qost) Oil as an Iranian Traditional Medicine Product on Female Urinary Incontinence; Double Blinded Randomized Clinical Trial

Document Type : Original paper


1 Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran.

2 Department of Pelvic Floor, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

3 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

4 School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Background and objectives: Urinary incontinence is a public complaint that causes discomfort, embarrassment and costs. Also, there are some limitations and insufficiencies of drug therapy and surgical complications. This study has compared the effect ofSaussurea costus (qost) oil as an Iranian traditional medicine product and other contemporary medicine treatment methods on female urinary incontinence. Methods: A parallel double blinded placebo-controlled study was conducted. Thirty to 70 years old women with urinary incontinence were allocated in placebo and intervention groups, 41 patients in each group.Intervention and placebo groups received qost oil and placebo, respectively by local application twice daily below the navel without massage. The results were evaluated with valid questionnaires (ICIQ-SF and I-QOL). For evaluation, Chi-square test, independent-sample t-test and repeated measure analysis of variance were used. Significant p value was Results: A significant decrease in mean scores of the questionnaires during the study was noted in the qost group compared to the placebo group (p<0.001). Before the intervention, thirty one patients in the placebo group and 33 patients in the qost group had mixed urinary incontinence (p=0.794). Urge symptom s(nocturia, urine frequency and urgency to urination)  were completely discontinued in 25 patients in the qost group (78.1%) and 7 patients in the placebo group (22.6%) (p<0.001). Conclusion: The results suggested the oil to be effective in treatment of urinary inconsistence. 


Main Subjects

[1] Norton P, Brubaker A. Urinary incontinence in women. Lancet. 2006; 367(9504): 57-67.
[2] Legendre G, Ringa V, Fauconnier A, Fritel X. Menopause, hormone treatment and urinary incontinence at midlife. Maturitas. 2013; 74(1): 26-30.
[3] European Association of Urology. Guidelines on Urinary Incontinence. [Accessed 2015]. Available from: http://www.uroweb.org/guidelines/online-guidelines/.
[4] Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbel-Walsh Urology, 11th ed. Philadelphia: Elsevier, 2016.
[5] Abrams P, Smith AP, Cotterill N.The impact of urinary incontinence on health-related quality of life (HRQoL) in a real-world population of women aged 45-60 years: results from a survey in France, Germany, the UK and the USA. BJU International. 2015; 115(1): 143-150.                    
[6] Ronald SG, Karlyn BY, Haney AF, Nygaard I. Danforth’ obstetrics and gynecology. 10th ed. Philadelphia: Lippincott Williams &Wilkins, 2008.
[7] Cameron AP, Haraway AM. The treatment of female stress urinary incontinence: an evidenced-based review. Open Access J Urol. 2011; 17(3): 109-120.
[8] Alvarez-Bandrés S, Hualde-Alfaro A, Jiménez-Calvo J, Cebrián-Lostal JL, Jiménez-Parra JD, García-García D, Montesino-Semper M. Complications of female urinary incontinence surgery with mini-sling system. Actas Urol Esp. 2010; 34 (10): 893-897.
[9] Matthews L, Shapiro R, Zaslau S. Pharmacologic management of overactive bladder and urge incontinence: a review of new and old treatment options. J Androl Gynaecol. 2014; 2(1): 1-4.
[10] Bagheri S, Ebadi N, Taghipour Z, Manayi A, Toliyat T, Mirabzadeh Ardakani M. Preparation of Saussurea costus traditional oil and investigation of different parameters for standardization. Res J Pharmacogn. 2018; 5(2): 51-56.
[11] Hajebrahimi S, Nourizadeh D, Hamedani R, Pezeshki MZ. Validity and reliability of the internatinal consultation on incontinence questionairre-urinary incoctinence short form and its corrrelation with urodynamic findings. Urol J. 2012; 9(4): 685-690.
[12] Nojomi M, Baharvand P, Moradi Lakeh M, Patrick DL. Incontinence quality of life questionnaire (I-QOL): translation and validation study of the Iranian version. Int Urogynecol J Pelvic Floor Dysfunct. 2009; 20(5): 575-579.    
[13] Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004; 23(4): 322-330.
[14] Tamanini JN, Dambros M, D’anconaca L. Responsiueness to the Portuguese version of the international consultation on incontinence questionnaire - short form (ICIQ-SF) after stress urinary incontinence surgery. Int Braz J Urol. 2005; 31(5): 482-490.
[15] Avicenna H. Al-qanun fi-alteb. 1st ed. Beirut: Al-Alami Library, 2005.
[16] Tabarrai M, Niktabe Z, Masoudi N, Eftekhaar T, Shirbeigi L. Female stress urinary incontinence in Iranian traditional medicine, its prevention and comparison to modern medicine. Med Hist. 2016; 8(26): 49-75.
[17] Aghili M. Makhzan-aladveeh. 2nd ed. Tehran: Sabzarang, 2009.
[18] Sarwar A, Enbergs H. Effects of Saussurea lappa roots extract in ethanol on leukocyte phagocytic activity, lymphocyte proliferation and interferon-gamma (IFN-gamma). Pak J Pharm Sci. 2007; 20(3): 175-179.
[19] Gokhale AB, Damre AS, Kulkami KR, Saraf MN. Preliminary evaluation of anti-inflammatory and anti-arthritic activity of S. lappa, A. speciosa and A. aspera. Phytomed. 2002; 9(5): 433-437.
[20] Akhtar MS, Bashir S, Malik MN, Manzoor R. Cardiotonic activity of methanolic extract of Saussurea lappa Linn roots. Pak J Pharm Sci. 2013; 26(6): 1197-1201.
[21] Qiu J, Wang J, Luo H, Du X, Li H, Luo M, Dong J, Chen Z, Deng X. The effects of subinhibitory concentrations of costus oil on virulence factor production in Staphylococcus aureus. J Appl Microbiol. 2011;(110)1: 333-340.            
[22] Hersh L, Salzman B. Clinical management of urinary incontinence in women. Am Fam Physician. 2013; 87(9): 634-640.
[23] Sirls LT, Foote JE, Kaufman JM, Lightner DJ, Miller JL, Moseley WG, Nygaard IE, Steidle CP. Long-term results of the FemSoft urethral insert for the management of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2002; 13(2): 88-95.
[24] DeMaagd G. Urinary incontinence: treatment update with a focus on pharmacological management. US Pharm. 2007; 32(6): 34-44.
[25] Cochrane Database Syst Rev. Adrenergic drugs for urinary incontinence in adults. [Accessed 2005]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12804414.
[26] Gibbs CF, Johnson TM, Ouslander JG. Office management of geriatric urinary incontinence. Am J Med. 2007; 120(3): 211-220.
[27] Campanelli CM. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012; 60(4): 616-631.
[28] Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012; 4(6): 315-324.
[29] Weiss BD. Selecting medications for the treatment of urinary incontinence. Am Fam Physician. 2005; 71(2): 315-322.
[30] Cochrane Database Syst Rev. Oestrogen therapy for urinary incontinence in post-menopausal women. [Accessed 2012]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23076892.
[31] Joshua AC, Elizabeth TB, Reynolds WS, Melissa RK, Milam DF, Dmochowski RR. An update on the use of transdermaloxybutynin in the management of overactive bladder disorder. Ther Adv Urol.2016; 8(2): 83-90.